Erythropoietin inhibits neutrophil extracellular traps formation to ameliorate lung injury in a pneumonia model
Main Article Content
Keywords
erythropoietin (epo), lung injury, neutrophil extracellular trapping (nets), pneumonia, TRAF2/NF-κB
Abstract
Background: Severe pneumonia is a kind of disease that develops from lung inflammation, and new drugs are still required to treat the same. Erythropoietin (EPO) is widely used to treat anemia in patients. However, there are fewer studies on the role of EPO in neutrophil extracellular trappings (NETs) and pneumonia, and the mechanism is unclear.
Objective: To investigate the possible effects of EPO on the formation of NETs and progression of pneumonia.
Methods: Mice pneumonia model was induced by tracheal lipopolysaccharide (LPS) administration. Hematoxylin and eosin (H&E) staining and automatic blood cell analysis were performed in this model to confirm the effects of EPO on lung injury. Flow cytometry, enzyme-linked immunosorbent serological assay, and immunostaining assay were conducted to detect the effects of EPO on the inflammation as well as formation of NETs in mice. Immunoblot was further conducted to confirm the mechanism.
Results: EPO alleviated LPS-induced lung injury. EPO reduced the release of inflammatory factors induced by LPS. In addition, EPO inhibited the formation of NETs. Mechanically, EPO inhibited tumor necrosis factor (TNF) receptor associated factor 2 (TRAF2)/nuclear factor kappa-B (NF-κB) activity in mouse models, and therefore suppressed the progression of pneumonia.
Conclusion: EPO inhibited formation of NETs to ameliorate lung injury in a pneumonia model, and could serve as a drug of pneumonia.
References
2. Rasouli S, Heshmatnia J, Mosaffa N, Marjani M, Mortaz E. Dysregulation of immunity in pulmonary fibrosis is associated with increased myeloid-specific triggering receptor-1 and transforming growth factor-beta 1 expression. Iran J Allergy Asthma Immunol. 2023;22(1):12–24. 10.18502/ijaai.v22i1.12002
3. Miethe S, Potaczek DP, Bazan-Socha S, Bachl M, Schaefer L, Wygrecka M, et al. The emerging role of extracellular vesicles as communicators between adipose tissue and pathologic lungs with a special focus on asthma. Am J Physiol Cell Physiol. 2023;324:C1119–25. 10.1152/ajpcell.00057.2023
4. Luan Y, Liu H, Luan Y, Yang Y, Yang J, Ren KD. New insight in HDACs: Potential therapeutic targets for the treatment of atherosclerosis. Front Pharmacol. 2022;13:863677. 10.3389/fphar.2022.863677
5. Sanders NL, Martin IMC, Sharma A, Jones MR, Quinton LJ, Bosmann M, et al. Neutrophil extracellular traps as an exacerbating factor in bacterial pneumonia. Inf Immun. 2022;90(3):e0049121. 10.1128/iai.00491-21
6. Pulavendran S, Rudd JM, Maram P, Thomas PG, Akhilesh R, Malayer JR, et al. Combination therapy targeting platelet activation and virus replication protects mice against lethal influenza pneumonia. Am J Resp Cell Mol Biol. 2019;61(6): 689–701. 10.1165/rcmb.2018-0196OC
7. Sung PS, Peng YC, Yang SP, Chiu CH, Hsieh SL. CLEC5A is critical in pseudomonas aeruginosa-induced NET formation and acute lung injury. JCI Insight. 2022;7(18). 10.1172/jci.insight.156613
8. Yao ME, Huang Y, Dong QQ, Lu Y, Chen W. The renshen chishao decoction could ameliorate the acute lung injury but could not reduce the neutrophil extracellular traps formation. Evidence Complement Alternat Med (eCAM). 2022;2022:7784148. 10.1155/2022/7784148
9. Duygu G, Yalcin-Ulker GM, Gunbatan M, Soluk-Tekkesin M, Ozcakir-Tomruk C. Evaluation of preventive role of systemically applied erythropoietin after tooth extraction in a bisphosphonate-induced MRONJ model. Medicina. 2023;59(6). 10.3390/medicina59061059
10. Chen H, Yu J, Wei Q, Zhang Y, Ouyang X, Wang S. Intravenous iron and erythropoietin therapy for postoperative anemia among orthopedic surgery patients. J Orthop Surg Res. 2023;18(1):510. 10.1186/s13018-023-03926-y
11. Skrifvars MB, Luethi N, Bailey M, French C, Nichol A, Trapani T, et al. The effect of recombinant erythropoietin on long-term outcome after moderate-to-severe traumatic brain injury. Intensive Care Med. 2023;49(7):831–9. 10.1007/s00134-023-07141-5
12. Horwitz JK, Bin S, Fairchild RL, Keslar KS, Yi Z, Zhang W, et al. Linking erythropoietin to treg-dependent allograft survival through myeloid cells. JCI Insight. 2022;7(10). 10.1172/jci.insight.158856
13. Li J, Yan W, Ren F, Sang H. Tectorigenin inhibits inflammation in keratinocytes by inhibition of NLRP3 inflammasome regulated by the TLR4/NF-kappaB pathway. Allergol Immunopathol (Madr). 2023;51(2):82–9. 10.15586/aei.v51i2.780
14. Liu L, Huan L, Zhang Y, Wei W, Chen Z, Xu D, et al. Ubiquitin-specific protease 8 inhibits lipopolysaccharide-triggered pyroptosis of human bronchial epithelial cells by regulating PI3K/AKT and NF-kappaB pathways. Allergol Immunopathol (Madr). 2022;50(2):96–103. 10.15586/aei.v50i2.568
15. Regua A, Papp C, Grageda A, Porter B, Caza T, Bichindaritz I, et al. ABI1-based expression signature predicts breast cancer metastasis and survival. Mol Oncol. 2021;16:2632-2657 10.1002/1878-0261.13175
16. Li C, Fan R, Li DB, Zhou W, Huang YE, Wang B. Intervention effects of erythropoietin derived peptide (HBSP) on renal injury induced by acute skeletal muscle strain in rats. Zhongguo ying yong sheng li xue za zhi. (Chin J Appl Physiol). 2022;38(6):617–21.
17. Cao F, Tian X, Li Z, Lv Y, Han J, Zhuang R, et al. Suppression of NLRP3 inflammasome by erythropoietin via the EPOR/JAK2/STAT3 pathway contributes to attenuation of acute lung injury in mice. Front Pharmacol. 2020;11:306. 10.3389/fphar.2020.00306
18. Jacobs RA, Aboouf MA, Koester-Hegmann C, Muttathukunnel P, Laouafa S, Arias-Reyes C, et al. Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice. Commun Biol. 2021;4(1):938. 10.1038/s42003-021-02465-8
19. Chen H, Luo B, Yang X, Xiong J, Liu Z, Jiang M, et al. Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol. 2014;268(1–2):64–70. 10.1016/j.jneuroim.2014.01.006
20. Wang S, Zhang C, Li J, Niyazi S, Zheng L, Xu M, et al. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. Cell Death Dis. 2017;8(4):e2725. 10.1038/cddis.2017.104
21. Wu X, Lv Y, Li Z, Yang Z. Serelaxin inhibits LPS-induced inflammatory response in cardiac fibroblasts by activating PPAR-gamma and suppressing NF-kappaB signaling pathway. J Cardiovas Pharmacol. 2023;82: 201-211.
22. Simon F, Floros N, Ibing W, Schelzig H, Knapsis A. Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system. Neural Regen Res. 2019;14(8):1309–12. 10.4103/1673-5374.253507
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.